Literature DB >> 21760761

Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion Medicine.

Susanne Hofmann1, Jochen Greiner.   

Abstract

SUMMARY: Allogeneic hematopoietic progenitor cell transplantation (HPCT) is a crucial therapeutic option in hematological malignancies, and the graft-versus-leukemia (GvL) effect builds the cornerstone of a long-lasting remission. Cyto-toxic T cells are known to be the primary effector cells in GvL. They recognize minor histocompatibility antigens (mHags) and tumor/leukemia-associated antigens. In case of disease relapse after HPCT, donor lymphocyte infusion (DLI) is an important treatment option for re-induction of remission. However, both treatments, HPCT and DLI carry the risk of morbidity and mortality due to graft-versus-host disease (GvHD) and severe infections. Therefore, the development of targeted adoptive immunotherapy with a lower risk of GvHD is needed, and several study groups are working on that topic.

Entities:  

Year:  2011        PMID： 21760761      PMCID： PMC3128149          DOI： 10.1159/000328898

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN： 1660-3796            Impact factor:   3.747


  101 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Tracking antigen-specific CD8+ T cells in the rat using MHC class I multimers.

Authors:  Valérie Duplan; Elsa Suberbielle; Catherine E Napper; Etienne Joly; Abdelhadi Saoudi; Daniel Gonzalez-Dunia
Journal:  J Immunol Methods       Date:  2006-12-22       Impact factor: 2.303

4.  A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.

Authors:  Björn de Rijke; Agnes van Horssen-Zoetbrood; Jeffrey M Beekman; Britt Otterud; Frans Maas; Rob Woestenenk; Michel Kester; Mark Leppert; Anton V Schattenberg; Theo de Witte; Elly van de Wiel-van Kemenade; Harry Dolstra
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 5.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation.

Authors:  G R Hill; J L Ferrara
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

Review 6.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

7.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

8.  Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.

Authors:  Fabio Ciceri; Chiara Bonini; Sarah Marktel; Elisabetta Zappone; Paolo Servida; Massimo Bernardi; Alessandra Pescarollo; Attilio Bondanza; Jacopo Peccatori; Silvano Rossini; Zulma Magnani; Monica Salomoni; Claudia Benati; Maurilio Ponzoni; Luciano Callegaro; Paolo Corradini; Marco Bregni; Catia Traversari; Claudio Bordignon
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

9.  Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Authors:  Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas C Palmer; Luca Gattinoni; Zhiya Yu; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

Review 10.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Authors:  Michael Boeckh; W Garrett Nichols; Genovefa Papanicolaou; Robert Rubin; John R Wingard; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742
View more
  2 in total

1.  A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.

Authors:  J J Scarisbrick; F L Dignan; S Tulpule; E D Gupta; S Kolade; B Shaw; F Evison; G Shah; E Tholouli; G Mufti; A Pagliuca; R Malladi; K Raj
Journal:  Bone Marrow Transplant       Date:  2014-10-13       Impact factor: 5.483

Review 2.  Increasing Role of Targeted Immunotherapies in the Treatment of AML.

Authors:  Jochen Greiner; Marlies Götz; Verena Wais
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.